Radiotherapy Market Analysis On Competitive Landscape 2019 By Accuray, Elekta, Varian Medical Systems, CIVCO Medical Solutions, CR Bard, Brainlab, Isoray Medical, Inc., Nordion, RaySearch Laboratories, Hitachi, Mevion Medical Systems

Global Radiotherapy market is fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market in order to sustain in long run. The report includes market shares of radiotherapy market for global, Europe, North America, Asia Pacific and South America.

New research report of Global radiotherapy market is predictable to reach USD 9.3 billion by 2024 from USD 5.2 billion in 2016, at a CAGR of 7.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Beam radiotherapy market has the largest market segment in radiotherapy market.

To request a free sample copy or view summary of this report, click the link below @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-radiotherapy-market

The global radiotherapy market is highly concentrated to a big player and rest to local players who cater to domestic markets only. Varian Medical Systems, Inc. dominated the radiotherapy market accounting for a highest market share in 2016. Other players in this market include Elekta AB, Accuray, Inc., CIVCO Medical Solutions, Brainlab AG, C. R. Bard, Inc., IsoRay Medical, Inc., Nordion, Inc., RaySearch Laboratories AB, PRECISIS AG, Mevion Medical Systems, Inc., Technicas Radiofiscas S.L., Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mitsubishi Electric Corporation, ProNova Solutions, LLC, ProTom International.

Radiation therapy sole purpose is to treat tumors by targeting high beam of radiation on the affected region with minimal exposure to surrounding tissues. Modern radiotherapy uses high technology to try to achieve optimal local tumor control whilst minimizing treatment side effects to an acceptably low level. Aspects of the technology used for this goal include: computer systems for three-dimensional treatment planning and simulation, with accurate radiation dose deposition models and facilities for optimization of external radiation beam or brachytherapy source distribution; computer-controlled linear accelerators with dynamic beam collimation systems for external beam treatment or systems such as remote after loading for brachytherapy; and the use of radiation response models to characterize the treatment outcome and to enable the prediction of treatment outcomes for future patients’ treatments.

Global Radiotherapy Market Drivers:

Some of the major factors driving theradiotherapy market are rising incidence of cancer, increasing acceptance of adaptive radiation therapy (ART), growing pool of geriatric population and increasing number of cancer treatment facilities. Also,increase in out-patient cancer facilities, increasing demand for better radiotherapy equipments, replacement of out dated products and increasing influx of government and private funding for radiotherapy technology are driving the growth of the radiotherapy market.

GROWING PREVALENCE OF CANCER

In recent years, the prevalence of cancer across the globe has increased considerably over a period of time. The rapidly increasing prevalence of cancer and the subsequent rise in chronic conditions are major factors driving the demand radiotherapy devices.

RISING AGING POPULATION

With increasing age, the patient pool for chronic disease is rising which includes the growth of cancer cases among the older population. Since, cancer incidence is increasing exponentially with advancing age, it is expected to affect the older population which will impact the growth of the older cancer patient pool.

Elekta AB:

Founded in 1972 and headquartered in Stockholm, Sweden by Lars Leksell and Laurent Leksell. Elekta is a provider of human care, which specialises in the treatment of cancers and brain disorders. It provides oncologists, radiation therapists, neurosurgeons, and other medical specialists with the aid of clinical solutions and tools.

Have Any Query? Inquire here @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-radiotherapy-market

Recent Developments:

1. In December 2016, Elekta, Stockholm's County Council and New Karolinska Solna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research and education and training within advanced radiation therapy.

2. In March 2016, Elekta announced the strategic partnership with Genesis care where, the later will acquire Elekta’s Leksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by Genesis Care cancer treatment centres in Australia, the UK and new markets.

Accuray:

Accuray, Inc. is the premier radiation oncology company which develops, manufactures and sells personalized treatment solutions such as the cyberKnife and tomotherapy systems, which are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. The cyberKnife system is designed to combine continual image guidance technology with a compact linear accelerator, or linac, which has the ability to move in three dimensions according to the treatment plan. The tomotherapy system operates on a ring gantry and combines integrated computed tomography, or CT, imaging with intensity modulated radiation therapy, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. Accuray was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Recent Developments:

1. In August 2016, Accuray announced the CE approval of Radixact Treatment Delivery System, Accuray Precision Treatment Planning System and iDMS Data Management System in Europe.

2. In June 2016, Accuray Incorporated announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System.

Questions? We’ll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-radiotherapy-market

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.